Patients with macular degeneration of the eyes are usually treated by injecting Ranibizumab injection or Compazine ophthalmic injection into the vitreous cavity, and the specific number of injections needs to be judged according to the actual situation.
1. Ranibizumab injection: This drug is commonly used in the clinic for the treatment of neovascular age-related macular degeneration, and the main way of administration is intravitreal injection. Generally, it is recommended that patients should take the injection once a month during the treatment period. If patients are unable to ensure monthly injection, they can also take the injection for 3 months and then every 3 months thereafter.
2. Compazine Ophthalmic Injection: The administration is the same as that of Ranibizumab Injection. It is generally recommended that patients receive one injection per month for three consecutive months starting with the first treatment, and then every three months thereafter. Some patients can adjust the injection time according to the actual situation after the initial three-month injection, and it is not necessary to give the drug continuously, but during this period, it is necessary to follow up strictly according to the doctor’s instructions.
In summary, macular degeneration of the eye is mainly injected by injecting drugs in the vitreous humor, due to the difficulty of the operation, it is recommended that patients go to the ophthalmology department of the local regular hospitals for treatment, so as to avoid adverse consequences.